Contineum Therapeutics (CTNM) Profit After Tax: 2023-2024
Historic Profit After Tax for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$14.6 million.
- Contineum Therapeutics' Profit After Tax fell 87.93% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 286.29%. This contributed to the annual value of -$42.3 million for FY2024, which is 286.18% down from last year.
- Per Contineum Therapeutics' latest filing, its Profit After Tax stood at -$14.6 million for Q4 2024, which was down 41.75% from -$10.3 million recorded in Q3 2024.
- In the past 5 years, Contineum Therapeutics' Profit After Tax ranged from a high of $41.6 million in Q2 2023 and a low of -$14.6 million during Q4 2024.
- Its 2-year average for Profit After Tax is -$2.5 million, with a median of -$8.1 million in 2023.
- Data for Contineum Therapeutics' Profit After Tax shows a maximum YoY slumped of 121.68% (in 2024) over the last 5 years.
- Over the past 2 years, Contineum Therapeutics' Profit After Tax (Quarterly) stood at -$7.8 million in 2023, then crashed by 87.93% to -$14.6 million in 2024.
- Its last three reported values are -$14.6 million in Q4 2024, -$10.3 million for Q3 2024, and -$9.0 million during Q2 2024.